Vanda’s Strong Results and Pipeline Catalysts Support Buy Rating; $20 Price Target Maintained
at www.tipranks.com (Mon, 2-Nov 10:26 AM)
VNDA spotlights Phase III HETLIOZ data: 37.1-minute sleep-onset improvement versus placebo in DSWPD
Market Chameleon (Wed, 30-Sep 7:06 AM)
